PriceTargets.com logo

Zynerba Pharmaceuticals - ZYNE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 1,656.63%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.63 As of 02/7/2023 01:00 AM ET
▲ +0.02 (3.30%)

This chart shows the closing price for ZYNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zynerba Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYNE

Analyst Price Target is $11.00
▲ +1,656.63% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 1,656.63% upside from the last price of $0.63.

This chart shows the closing price for ZYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Zynerba Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2022HC WainwrightDowngradeBuy ➝ NeutralLow
6/23/2022Canaccord Genuity GroupReiterated RatingBuy$9.00 ➝ $11.00Low
6/23/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$9.00 ➝ $11.00Low
11/18/2021HC WainwrightReiterated RatingBuy$9.00High
9/21/2021HC WainwrightReiterated RatingBuy$9.00Medium
9/13/2021UBS GroupReiterated RatingPositiveLow
5/6/2021Cantor FitzgeraldBoost TargetOverweight$6.00 ➝ $8.00High
3/10/2021Roth CapitalLower TargetBuy$8.00 ➝ $7.25High
12/21/2020HC WainwrightLower TargetBuy$12.00 ➝ $9.00Low
9/14/2020Needham & Company LLCReiterated RatingHoldMedium
8/10/2020Needham & Company LLCReiterated RatingHoldMedium
7/1/2020HC WainwrightReiterated RatingBuy$12.00Medium
7/1/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
7/1/2020Cantor FitzgeraldLower TargetOverweight$24.00 ➝ $8.00Medium
6/29/2020LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/28/2020Cantor FitzgeraldBoost TargetOverweight$21.00 ➝ $24.00High
5/22/2020Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $21.00High
4/16/2020Needham & Company LLCReiterated RatingBuy$16.00High
2/20/2020HC WainwrightReiterated RatingBuyLow
12/31/2019Roth CapitalInitiated CoverageBuy$12.00High
10/21/2019Needham & Company LLCInitiated CoverageBuy$18.00High
9/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00High
9/16/2019Jefferies Financial GroupReiterated RatingHold$11.00Low
5/31/2019Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $22.00Medium
5/30/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/6/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Low
4/30/2019Roth CapitalInitiated CoverageBuy$36.00High
3/18/2019HC WainwrightReiterated RatingBuyHigh
3/7/2019Cantor FitzgeraldReiterated RatingBuy$11.00Medium
12/17/2018Cantor FitzgeraldSet TargetBuy$21.00High
12/5/2018Cantor FitzgeraldSet TargetBuy$21.00Medium
11/13/2018HC WainwrightSet TargetBuy$23.00High
10/2/2018Cantor FitzgeraldReiterated RatingBuy$21.00Medium
9/21/2018Cantor FitzgeraldInitiated CoverageOverweight$21.00Medium
8/6/2018HC WainwrightSet TargetBuy$23.00High
8/2/2018Cantor FitzgeraldSet TargetBuy$20.00High
7/13/2018HC WainwrightSet TargetBuy$23.00High
7/5/2018HC WainwrightReiterated RatingBuy$23.00High
7/5/2018Cantor FitzgeraldSet TargetBuy$20.00High
5/9/2018Cantor FitzgeraldSet TargetBuy$20.00Medium
5/8/2018OppenheimerReiterated RatingHoldLow
4/25/2018Cantor FitzgeraldSet TargetBuy$20.00Low
4/16/2018HC WainwrightSet TargetBuy$23.00Medium
3/13/2018OppenheimerReiterated RatingHoldMedium
3/13/2018HC WainwrightSet TargetBuy$23.00Medium
3/12/2018Cantor FitzgeraldSet TargetBuy$20.00Medium
3/6/2018HC WainwrightSet TargetBuy$23.00High
3/5/2018Cantor FitzgeraldInitiated CoverageBuy$17.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/8/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zynerba Pharmaceuticals logo
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Read More

Today's Range

Now: $0.63
Low: $0.59
High: $0.64

50 Day Range

MA: $0.58
Low: $0.50
High: $0.67

52 Week Range

Now: $0.63
Low: $0.49
High: $2.94

Volume

505,733 shs

Average Volume

330,985 shs

Market Capitalization

$28.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Zynerba Pharmaceuticals?

The following sell-side analysts have issued reports on Zynerba Pharmaceuticals in the last year: Canaccord Genuity Group Inc., HC Wainwright, and StockNews.com.
View the latest analyst ratings for ZYNE.

What is the current price target for Zynerba Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Zynerba Pharmaceuticals in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 1,656.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting ZYNE will reach $11.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $11.00 for Zynerba Pharmaceuticals in the next year.
View the latest price targets for ZYNE.

What is the current consensus analyst rating for Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYNE will outperform the market and that investors should add to their positions of Zynerba Pharmaceuticals.
View the latest ratings for ZYNE.

What other companies compete with Zynerba Pharmaceuticals?

Other companies that are similar to Zynerba Pharmaceuticals include Celyad Oncology, Vaccinex, Acasti Pharma, FoxWayne Enterprises Acquisition and Aeglea BioTherapeutics. Learn More about companies similar to Zynerba Pharmaceuticals.

How do I contact Zynerba Pharmaceuticals' investor relations team?

Zynerba Pharmaceuticals' physical mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company's listed phone number is (484) 581-7505 and its investor relations email address is [email protected] The official website for Zynerba Pharmaceuticals is www.zynerba.com. Learn More about contacing Zynerba Pharmaceuticals investor relations.